Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy.
White K, Connor K, Meylan M, Bougoüin A, Salvucci M, Bielle F, O'Farrell AC, Sweeney K, Weng L, Bergers G, Dicker P, Ashley DM, Lipp ES, Low JT, Zhao J, Wen P, Prins R, Verreault M, Idbaih A, Biswas A, Prehn JHM, Lambrechts D, Arijs I, Lodi F, Dilcan G, Lamfers M, Leenstra S, Fabro F, Ntafoulis I, Kros JM, Cryan J, Brett F, Quissac E, Beausang A, MacNally S, O'Halloran P, Clerkin J, Bacon O, Kremer A, Chi Yen RT, Varn FS, Verhaak RGW, Sautès-Fridman C, Fridman WH, Byrne AT. White K, et al. Among authors: verreault m. Ann Oncol. 2023 Mar;34(3):300-314. doi: 10.1016/j.annonc.2022.11.008. Epub 2022 Dec 6. Ann Oncol. 2023. PMID: 36494005 Free article.
Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.
Dragowska WH, Verreault M, Yapp DT, Warburton C, Edwards L, Ramsay EC, Huxham LA, Minchinton AI, Gelmon K, Bally MB. Dragowska WH, et al. Among authors: verreault m. Breast Cancer Res Treat. 2007 Dec;106(3):319-31. doi: 10.1007/s10549-007-9502-2. Epub 2007 Mar 9. Breast Cancer Res Treat. 2007. PMID: 17347776
Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.
Verreault M, Schmitt C, Goldwirt L, Pelton K, Haidar S, Levasseur C, Guehennec J, Knoff D, Labussière M, Marie Y, Ligon AH, Mokhtari K, Hoang-Xuan K, Sanson M, Alexander BM, Wen PY, Delattre JY, Ligon KL, Idbaih A. Verreault M, et al. Clin Cancer Res. 2016 Mar 1;22(5):1185-96. doi: 10.1158/1078-0432.CCR-15-1015. Epub 2015 Oct 19. Clin Cancer Res. 2016. PMID: 26482041 Free PMC article.
Blood-brain barrier, cytotoxic chemotherapies and glioblastoma.
Dréan A, Goldwirt L, Verreault M, Canney M, Schmitt C, Guehennec J, Delattre JY, Carpentier A, Idbaih A. Dréan A, et al. Among authors: verreault m. Expert Rev Neurother. 2016 Nov;16(11):1285-1300. doi: 10.1080/14737175.2016.1202761. Epub 2016 Jul 4. Expert Rev Neurother. 2016. PMID: 27310463 Review.
ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.
Dréan A, Rosenberg S, Lejeune FX, Goli L, Nadaradjane AA, Guehennec J, Schmitt C, Verreault M, Bielle F, Mokhtari K, Sanson M, Carpentier A, Delattre JY, Idbaih A. Dréan A, et al. Among authors: verreault m. J Neurooncol. 2018 Jul;138(3):479-486. doi: 10.1007/s11060-018-2819-3. Epub 2018 Mar 8. J Neurooncol. 2018. PMID: 29520610
81 results